Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study)
Por:
Isla D, de las Penas R, Insa A, Marse R, Martinez-Banaclocha N, Mut P, Moran T, Sala M, Massuti B, Ortega A, Jurado J, Gomez-Codina J, Diz P, Artal A, Gutierrez V, Vazquez M, Vinolas N, Maestu I, Camps C, Alvarez R, Soto M, Ponce S, Provencio M
Publicada:
1 sep 2019
Resumen:
Objectives: Concomitant chemo-radiation is the standard treatment for unresectable stage III non-small cell lung cancer (LA-NSCLC), The aim of this study was to assess the safety and efficacy of oral vinorelbine and cisplatin (OVP) compared with etoposide and cisplatin (EP), both in combination with radiotherapy, in this setting.
Material and methods: An open-label, randomized phase II trial was undertaken including 23 hospitals in Spain. Adults with untreated unresectable stage III NSCLC were randomizedl:1 to receive: oral vinorelbine (days 1 and 8 with cisplatin on day 1 in 3-week cycles; 2 cycles of induction, 2 cycles in concomitance) or etoposide (days 1-5 and 29-32 with cisplatin on days 1 and 8 in 4-week cycles; 2 cycles in concomitance). Both groups received concomitant radiotherapy 2 Gy/day (66 Gy). The primary endpoint was progression free survival (PFS).
Results: One hundred and forty patients were enrolled. Sixty-nine patients received OVP and 71 received EP. Globally adverse events grade 3/4 per cycle were fewer in the vinorelbine arm (19.4%) than in the etoposide arm (62.6%) (p < 0.001). One patient (1.5%) in the OVP arm and 12 pts (17.6%) in the EP arm presented esophagitis grade 3/4 (p = 0.002). Median PFS was similar in both groups (10.8 [95% CI 7.7-13.8] and 9.6 months [95% CI 4.4-14.8]; p = 0.457, respectively). Preliminary median overall survival was 30 months in the OVP arm and 31.9 months in the EP arm (p = 0.688).
Conclusions: Our findings show that OVP could be considered a standard combination with similar efficacy and better safety profile for the treatment of LA-NSCLC patients.
Filiaciones:
Isla D:
Univ Hosp Clin Lozano Blesa, Med Oncol, Zaragoza, Spain
de las Penas R:
Prov Hosp Castellon, Med Oncol, Castellon de La Plana, Spain
Insa A:
Univ Hosp Clin, Med Oncol, Valencia, Spain
Marse R:
Univ Hosp Son Espases, Med Oncol, Palma De Mallorca, Spain
Martinez-Banaclocha N:
Gen Univ Hosp Elche, Med Oncol, Elche, Spain
Mut P:
Hosp Son Llatzer, Med Oncol, Palma De Mallorca, Spain
Moran T:
Univ Autonoma Barcelona, Catalan Inst Oncol, Hosp Univ Germans Triasi Pujol, Med Oncol, Badalona, Spain
Sala M:
Univ Hosp Basurto, Med Oncol, Bilbao, Spain
Massuti B:
Gen Univ Hosp Alicante, Med Oncol, Alicante, Spain
Ortega A:
Hospital Complex Jaen, Med Oncol, Jaen, Spain
Jurado J:
Univ Hosp San Cecilio, Med Oncol, Granada, Spain
Gomez-Codina J:
Univ & Polytech Hosp La Fe, Med Oncol, Valencia, Spain
Diz P:
Assistent Complex Leon, Med Oncol, Leon, Spain
Artal A:
Univ Hosp Miguel Servet, Med Oncol, Zaragoza, Spain
Gutierrez V:
Reg Univ Hosp Malaga, Med Oncol, Malaga, Spain
Vazquez M:
Univ Hospitality Complex Santiago, Med Oncol, Santiago De Compostela, Spain
Vinolas N:
Univ Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
Maestu I:
Univ Hosp Doctor Peset, Med Oncol, Valencia, Spain
Camps C:
Univ Valencia, Gen Univ Hosp Valencia, Ctr Invest Biomed Red Canc, Med Oncol,Dept Med, Valencia, Spain
Alvarez R:
Gen Univ Hosp Gregorio Maranon, Med Oncol, Madrid, Spain
Soto M:
Univ Hosp Principe Asturias, Med Oncol, Madrid, Spain
Ponce S:
Univ Hosp 12 Ocutbre, Med Oncol, Madrid, Spain
Provencio M:
Univ Hosp Puerta Hierro, Med Oncol, Majadahonda Med Oncol, SLCG, Majadahonda, Spain
|